315 related articles for article (PubMed ID: 34420859)
1. Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments.
Reuss JE; Gosa L; Liu SV
Clin Lung Cancer; 2021 Nov; 22(6):483-499. PubMed ID: 34420859
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC).
Abuhelwa Z; Alloghbi A; Nagasaka M
Cancer Treat Rev; 2022 May; 106():102393. PubMed ID: 35472631
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic Class.
Marks JA; Wilgucki M; Liu SV; Reuss JE
Curr Oncol Rep; 2022 Dec; 24(12):1829-1841. PubMed ID: 36197593
[TBL] [Abstract][Full Text] [Related]
4. Pioneering the Way: The Revolutionary Potential of Antibody-Drug Conjugates in NSCLC.
Chen X; Zeng C
Curr Treat Options Oncol; 2024 Apr; 25(4):556-584. PubMed ID: 38520605
[TBL] [Abstract][Full Text] [Related]
5. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).
Parisi C; Mahjoubi L; Gazzah A; Barlesi F
Cancer Treat Rev; 2023 Jul; 118():102572. PubMed ID: 37230055
[TBL] [Abstract][Full Text] [Related]
6. Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach.
Marks S; Naidoo J
Lung Cancer; 2022 Jan; 163():59-68. PubMed ID: 34923203
[TBL] [Abstract][Full Text] [Related]
7. Antibody-Drug Conjugates-A Tutorial Review.
Baah S; Laws M; Rahman KM
Molecules; 2021 May; 26(10):. PubMed ID: 34063364
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates: Principles and opportunities.
Phuna ZX; Kumar PA; Haroun E; Dutta D; Lim SH
Life Sci; 2024 Jun; 347():122676. PubMed ID: 38688384
[TBL] [Abstract][Full Text] [Related]
9. Antibody-drug conjugates in advanced lung cancer: Is this a new frontier?
Reuss JE; Rosner S; Levy BP
Clin Adv Hematol Oncol; 2024 Jun; 22(5):217-226. PubMed ID: 38805313
[TBL] [Abstract][Full Text] [Related]
10. [Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer].
Wang N; Zhao L; Zhang D; Jia Y; Kong F
Zhongguo Fei Ai Za Zhi; 2022 Mar; 25(3):214-218. PubMed ID: 35340165
[TBL] [Abstract][Full Text] [Related]
11. 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.
Verma S; Breadner D; Raphael J
Curr Oncol; 2023 Apr; 30(4):4329-4350. PubMed ID: 37185443
[TBL] [Abstract][Full Text] [Related]
12. Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
Desai A; Abdayem P; Adjei AA; Planchard D
Lung Cancer; 2022 Jan; 163():96-106. PubMed ID: 34942494
[TBL] [Abstract][Full Text] [Related]
13. The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy.
Liu X; Deng J; Zhang R; Xing J; Wu Y; Chen W; Liang B; Xing D; Xu J; Zhang M
Front Immunol; 2023; 14():1335252. PubMed ID: 38162667
[TBL] [Abstract][Full Text] [Related]
14. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma.
Yu B; Liu D
J Hematol Oncol; 2019 Sep; 12(1):94. PubMed ID: 31500657
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies.
Passaro A; Jänne PA; Peters S
J Clin Oncol; 2023 Jul; 41(21):3747-3761. PubMed ID: 37224424
[TBL] [Abstract][Full Text] [Related]
16. More than Toxins-Current Prospects in Designing the Next Generation of Antibody Drug Conjugates.
Schwach J; Abdellatif M; Stengl A
Front Biosci (Landmark Ed); 2022 Aug; 27(8):240. PubMed ID: 36042167
[TBL] [Abstract][Full Text] [Related]
17. Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.
Kumari S; Raj S; Babu MA; Bhatti GK; Bhatti JS
Arch Pharm Res; 2024 Jan; 47(1):40-65. PubMed ID: 38153656
[TBL] [Abstract][Full Text] [Related]
18. A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers.
Liu K; Li M; Li Y; Li Y; Chen Z; Tang Y; Yang M; Deng G; Liu H
Mol Cancer; 2024 Mar; 23(1):62. PubMed ID: 38519953
[TBL] [Abstract][Full Text] [Related]
19. Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors.
Nelson BE; Meric-Bernstam F
Annu Rev Med; 2024 Jan; 75():31-48. PubMed ID: 37758237
[TBL] [Abstract][Full Text] [Related]
20. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
Chen H; Lin Z; Arnst KE; Miller DD; Li W
Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]